FMI - Foundation Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
137.00
+0.20 (+0.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close136.80
Open136.80
Bid0.00 x 0
Ask0.00 x 0
Day's Range136.75 - 137.00
52 Week Range35.10 - 137.20
Volume609,897
Avg. Volume657,445
Market Cap5.088B
Beta1.54
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Best Biotech Acquisitions of 2018 (So Far)
    Motley Foollast month

    3 Best Biotech Acquisitions of 2018 (So Far)

    There were bigger biotech deals than these this year, but arguably none better.

  • Motley Fool2 months ago

    What Roche's Acquisition of Foundation Medicine Means for Investors

    Roche makes a big bet on precision oncology.

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks2 months ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Motley Fool2 months ago

    Big Biotech Stock Pops and Drops This Week

    Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.

  • The Wall Street Journal2 months ago

    [$$] Gormley's Take: Precision-Medicine Drive Gathers Momentum

    Last month, the American Cancer Society expanded opportunities for colorectal cancer-testing companies when it called for people with average risk profiles to begin screening at age 45 instead of 50. Inc., which went public in 2005, said clinical trials showed its Oncotype DX test could definitively identify which early-stage breast cancer patients would and wouldn’t benefit from chemotherapy—news that propelled its stock price to all-time highs. Inc., which Third Rock Ventures formed in 2009 and took public in 2013.

  • Company News For Jun 20, 2018
    Zacks2 months ago

    Company News For Jun 20, 2018

    Companies in the news are: T,FMI,COTV,SRPT

  • Roche to Buy Rest of Foundation Medicine for $2.4 billion
    Zacks2 months ago

    Roche to Buy Rest of Foundation Medicine for $2.4 billion

    Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.

  • The Wall Street Journal2 months ago

    [$$] Roche to Pay $2.4 Billion for Full Control of Foundation Medicine

    Roche Holding AG on Tuesday said it would pay $2.4 billion to buy the shares it doesn’t already own in Foundation Medicine Inc., furthering its bet on personalized cancer care. The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer.

  • Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today
    Motley Fool2 months ago

    Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today

    Find out why healthcare made a big leap in today's market action.

  • How A Merger Will Help These Two Firms Tailor Cancer Treatments
    Investor's Business Daily2 months ago

    How A Merger Will Help These Two Firms Tailor Cancer Treatments

    Foundation Medicine rocketed to a record high Tuesday after Swiss drugmaker Roche agreed to buy it in a pharmaceutical merger for $2.4 billion.

  • Roche Does Pharma M&A Without the Pharma
    Bloomberg2 months ago

    Roche Does Pharma M&A Without the Pharma

    The Swiss giant agreed Tuesday to pay $2.4 billion to buy out the remaining shareholders in Foundation Medicine Inc., a cancer-focused gene sequencing company in which it holds a more than 50 percent stake. It follows Roche's $1.9 billion purchase earlier this year of Flatiron Health Inc., which collects and analyzes real-world data on how cancer patients are treated. These were Roche’s two biggest deals since 2014. The Foundation deal comes at a hefty premium, and may be a disappointment to investors who would have preferred a more typical acquisition focused on an actual, existing drug.

  • Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today
    Motley Fool2 months ago

    Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today

    The company's being acquired by long-time partner Roche Holdings.

  • Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups
    Yahoo Finance2 months ago

    Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups

    Netflix, Amazon, Wells Fargo, Roche and Apple are the companies to watch.

  • Stocks fall deep into the red as trade war escalates
    Yahoo Finance2 months ago

    Stocks fall deep into the red as trade war escalates

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • The Wall Street Journal2 months ago

    [$$] European Corporate Roundup for Tuesday

    A $2.4 billion Roche acquisition and another Debenhams profit warning are the European corporate highlights Tuesday.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters2 months ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the U.S. genomic profiling group's ability to personalise cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.

  • The Wall Street Journal2 months ago

    [$$] Roche to Buy Rest of Foundation Medicine

    The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer. The deal to take full control of Foundation comes after Roche first bought a stake in the company in 2015.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters2 months ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche (ROG.S) is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) (FMI.O), raising its bet on the U.S. genomic profiling group's ability to personalize cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.

  • 5 Top Performing Stocks of the Best ETF of May
    Zacks3 months ago

    5 Top Performing Stocks of the Best ETF of May

    Inside the best performing stocks of the top ETF of May - ARKG.

  • 3 Stocks That Look Just Like eBay in 1998
    Motley Fool3 months ago

    3 Stocks That Look Just Like eBay in 1998

    These stocks are revolutionizing industries and that could make them great long-term stocks to add to your portfolio.

  • Mattel, Foundation Medicine and Sirius are the Yahoo Finance Charts of the day.
    Yahoo Finance Video2 months ago

    Mattel, Foundation Medicine and Sirius are the Yahoo Finance Charts of the day.

    Let's check out the Yahoo Finance charts of the day. Mattel (MAT): Shares are down in early trade, at around 2.9%.  The toy maker was downgraded to "neutral" from "buy" at UBS, which still sees value in the brand but notes the stock's 35 percent jump from its March lows despite little change in fundamentals. Foundation Medicine (FMI): Shares up here, around 28.5%.  Roche Holding said it would pay $2.4 billion to buy the shares it doesn't already own in Foundation Medicine. The Swiss drug giant presently owns 57% of Foundation and will pay $137 a share for the U.S based company. Sirius (SIRI): Shares down here, at around 1.7%. The satellite radio operator was downgraded to "hold" from "buy" at Pivotal Research in a valuation call. Pivotal's target price for the Sirius stock remains at $7.75 per share. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Netflix expands and has price target raised, Amazon teams up with Marriott hotels, Wells Fargo merging wealth management groups
    Yahoo Finance Video2 months ago

    Netflix expands and has price target raised, Amazon teams up with Marriott hotels, Wells Fargo merging wealth management groups

    Netflix, Amazon, Wells Fargo, Roche and Apple are the companies to watch.